Insider trades › Songjiang Ma
Songjiang Ma
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing May 29, 2025
Companies
1
where this person reports as an insider
Open-market buys
0
among the latest 83 trades
Open-market sales
83
among the latest 83 trades
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Songjiang Ma's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Songjiang Ma bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Songjiang Ma?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| Company | Role | Last filed |
|---|---|---|
| GYRE Gyre Therapeutics, Inc. | President, Director | May 29, 2025 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| May 28, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 558 | $10.07 | $5,619 | -82.7% | Form 4 ↗ |
| May 27, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.28 | $20.6K | -85.3% | Form 4 ↗ |
| May 23, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 182 | $10.24 | $1,864 | -80.6% | Form 4 ↗ |
| May 22, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.97 | $21.9K | -90.9% | Form 4 ↗ |
| May 21, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.83 | $21.7K | -87.9% | Form 4 ↗ |
| May 20, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.25 | $22.5K | -89.4% | Form 4 ↗ |
| May 19, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.11 | $22.2K | -88.0% | Form 4 ↗ |
| May 16, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.31 | $22.6K | -89.0% | Form 4 ↗ |
| May 15, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.68 | $21.4K | -88.4% | Form 4 ↗ |
| May 14, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 20 | $11.30 | $226 | -86.9% | Form 4 ↗ |
| May 13, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.37 | $22.7K | -91.1% | Form 4 ↗ |
| May 12, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.56 | $21.1K | -89.6% | Form 4 ↗ |
| Mar 21, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 174 | $10.00 | $1,740 | -89.4% | Form 4 ↗ |
| Mar 20, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.09 | $20.2K | -91.2% | Form 4 ↗ |
| Mar 19, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.13 | $20.3K | -91.1% | Form 4 ↗ |
| Mar 18, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 242 | $10.24 | $2,478 | -84.2% | Form 4 ↗ |
| Mar 17, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.09 | $24.2K | -97.9% | Form 4 ↗ |
| Mar 14, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.31 | $24.6K | -98.4% | Form 4 ↗ |
| Mar 13, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.80 | $23.6K | -100.8% | Form 4 ↗ |
| Mar 12, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.74 | $23.5K | -98.0% | Form 4 ↗ |
| Mar 11, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.40 | $22.8K | -97.7% | Form 4 ↗ |
| Mar 10, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.14 | $20.3K | -92.8% | Form 4 ↗ |
| Mar 7, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,906 | $10.13 | $19.3K | -89.2% | Form 4 ↗ |
| Mar 7, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 53 | $13.03 | $691 | -89.2% | Form 4 ↗ |
| Mar 7, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 41 | $12.14 | $498 | -89.2% | Form 4 ↗ |
| Mar 6, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.80 | $21.6K | -91.4% | Form 4 ↗ |
| Mar 5, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.98 | $22.0K | -90.6% | Form 4 ↗ |
| Mar 4, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.86 | $21.7K | -91.2% | Form 4 ↗ |
| Mar 3, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.23 | $22.5K | -91.5% | Form 4 ↗ |
| Feb 28, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.41 | $22.8K | -89.8% | Form 4 ↗ |
| Feb 27, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.33 | $22.7K | -90.8% | Form 4 ↗ |
| Feb 26, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.63 | $23.3K | -89.4% | Form 4 ↗ |
| Feb 25, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.37 | $22.7K | -89.3% | Form 4 ↗ |
| Feb 24, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,813 | $10.60 | $19.2K | -85.5% | Form 4 ↗ |
| Feb 24, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 187 | $11.52 | $2,154 | -85.5% | Form 4 ↗ |
| Feb 21, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,818 | $11.84 | $21.5K | -88.4% | Form 4 ↗ |
| Feb 21, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 182 | $12.60 | $2,293 | -88.4% | Form 4 ↗ |
| Feb 20, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.40 | $24.8K | -89.3% | Form 4 ↗ |
| Feb 19, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.29 | $24.6K | -87.6% | Form 4 ↗ |
| Feb 18, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.49 | $25.0K | -89.4% | Form 4 ↗ |
| Feb 14, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.94 | $23.9K | -87.8% | Form 4 ↗ |
| Feb 13, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.69 | $23.4K | -87.1% | Form 4 ↗ |
| Feb 12, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.49 | $23.0K | -87.9% | Form 4 ↗ |
| Feb 11, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,878 | $11.52 | $21.6K | -87.4% | Form 4 ↗ |
| Feb 10, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.90 | $23.8K | -88.5% | Form 4 ↗ |
| Feb 7, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.16 | $24.3K | -89.9% | Form 4 ↗ |
| Feb 6, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.85 | $25.7K | -90.6% | Form 4 ↗ |
| Feb 5, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 20 | $12.84 | $257 | -91.2% | Form 4 ↗ |
| Feb 5, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,980 | $12.39 | $24.5K | -91.2% | Form 4 ↗ |
| Feb 4, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.62 | $23.2K | -89.1% | Form 4 ↗ |
| Feb 3, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.47 | $22.9K | -88.9% | Form 4 ↗ |
| Jan 31, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.51 | $23.0K | -87.9% | Form 4 ↗ |
| Jan 30, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.37 | $22.7K | -87.2% | Form 4 ↗ |
| Jan 29, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.43 | $22.9K | -87.8% | Form 4 ↗ |
| Jan 28, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.51 | $23.0K | -88.1% | Form 4 ↗ |
| Jan 27, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.18 | $22.4K | -88.0% | Form 4 ↗ |
| Jan 24, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.89 | $21.8K | -85.6% | Form 4 ↗ |
| Jan 23, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.49 | $21.0K | -83.1% | Form 4 ↗ |
| Jan 22, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.63 | $21.3K | -84.1% | Form 4 ↗ |
| Jan 21, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.85 | $21.7K | -85.8% | Form 4 ↗ |
| Jan 17, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.72 | $21.4K | -86.9% | Form 4 ↗ |
| Jan 16, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.71 | $21.4K | -87.6% | Form 4 ↗ |
| Jan 15, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.85 | $21.7K | -87.8% | Form 4 ↗ |
| Jan 14, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.39 | $20.8K | -88.6% | Form 4 ↗ |
| Jan 13, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 56 | $10.10 | $566 | -86.6% | Form 4 ↗ |
| Jan 10, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,057 | $10.02 | $10.6K | -86.8% | Form 4 ↗ |
| Jan 3, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 833 | $11.85 | $9,871 | -87.5% | Form 4/A ↗ |
| Jan 7, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 1,275 | $10.02 | $12.8K | -85.0% | Form 4 ↗ |
| Jan 6, 2025 | GYRE Gyre Therapeutics, Inc. | Sale | 941 | $10.16 | $9,561 | -82.4% | Form 4 ↗ |
| Dec 31, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.30 | $24.6K | -93.1% | Form 4 ↗ |
| Dec 30, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.50 | $25.0K | -94.2% | Form 4 ↗ |
| Dec 27, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $12.58 | $25.2K | -92.2% | Form 4 ↗ |
| Dec 26, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 1,644 | $12.62 | $20.7K | -92.6% | Form 4 ↗ |
| Dec 26, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 356 | $13.05 | $4,646 | -92.6% | Form 4 ↗ |
| Dec 24, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $11.93 | $23.9K | -89.2% | Form 4 ↗ |
| Dec 23, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 1,704 | $12.24 | $20.9K | -91.5% | Form 4 ↗ |
| Dec 23, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 296 | $12.44 | $3,682 | -91.5% | Form 4 ↗ |
| Dec 20, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.90 | $21.8K | -88.9% | Form 4 ↗ |
| Dec 19, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 2,000 | $10.82 | $21.6K | -88.3% | Form 4 ↗ |
| Dec 18, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 1,571 | $11.17 | $17.5K | -88.4% | Form 4 ↗ |
| Dec 18, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 429 | $12.11 | $5,195 | -88.4% | Form 4 ↗ |
| Dec 17, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 1,212 | $10.94 | $13.3K | -86.1% | Form 4 ↗ |
| Dec 17, 2024 | GYRE Gyre Therapeutics, Inc. | Sale | 788 | $11.23 | $8,849 | -86.1% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.